Transaction DateRecipientSharesTypePriceValue
8th September 2020Ankit Mahadevia774Open or private sale$14.25$11,029.73
8th September 2020Ankit Mahadevia774Exercise of derivative$5.90$4,566.60
9th July 2020Ankit Mahadevia2,293Exercise of derivative$5.90$13,528.70
9th July 2020Ankit Mahadevia2,293Open or private sale$14.31$32,806.64
7th July 2020Ankit Mahadevia754Open or private sale$14.25$10,744.95
7th July 2020Ankit Mahadevia754Exercise of derivative$5.90$4,448.60
25th June 2020Ankit Mahadevia2,642Open or private sale$14.25$37,650.35
25th June 2020Ankit Mahadevia2,642Exercise of derivative$5.90$15,587.80
24th June 2020Ankit Mahadevia3,880Open or private sale$14.28$55,419.59
24th June 2020Ankit Mahadevia3,880Exercise of derivative$5.90$22,892.00
Spero Therapeutics
Spero Therapeutics logo

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013.

Ticker: SPRO
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1701108
Employees: 57
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags